Catalent launches FastChain service
New service meets the increasing demand for speed and flexibility in global clinical trials.
Catalent Pharma Solutions has launched its FastChain service, for greater speed, flexibility and efficiency in the management of global clinical supplies.
Based upon the company’s demand led supply model, FastChain is a continuous GMP approach to clinical supply management that decouples primary packaging from secondary packaging, and enables the final assembly, labeling and distribution of clinical supplies on a regional basis. This approach reduces the need to pre-package bulk supplies far in advance of the study start, creates the ability to pool supplies across protocols, and has the potential to reduce clinical waste from upwards of 200% or more to less than 20%.
Investigator sites will receive only the clinical supplies they need to meet actual patient demand within a matter of days rather than weeks. Furthermore, mid-study changes such as revised dosing schedules or the addition of countries and clinical sites will be easy to accommodate for FastChain customers.
“Catalent is already performing global demand led supply services on behalf of a major pharmaceutical customer and will now introduce its unique FastChain service to bring demand led supply to the broader industry,” stated Wetteny Joseph, President, Catalent Clinical Supply Services. “We have seen significant interest from companies of all sizes who are looking for more flexible and innovative solutions to get to the clinic faster.”
Catalent will continue to make significant investments in its facilities worldwide to include specialized packaging lanes, and integrated systems and processes to support demand led studies and will make the FastChain service available for both ambient and cold chain studies on a global basis.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance